Merck & Co., Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MRCK34.SA | AZN | PFE | GLAXO.NS | JNJ.DE | 0QYQ.IL | |
|---|---|---|---|---|---|---|
| Market cap | 2.05T | 293.14B | 175.50B | 423.55B | 597.86B | 219.86B |
| P/E (TTM) | 159.4 | 26.7 | 44.0 | 36.9 | 43.8 | 40.6 |
| Forward P/E | — | 16.7 | 10.6 | 31.6 | — | — |
| Price/book | 9.7 | 5.7 | 2.1 | 22.5 | 8.2 | 10.4 |
| Dividend yield | 1.44% | 1.69% | 5.59% | 2.25% | 1.99% | 3.81% |
| 1-year change | +81.66% | +12.81% | +23.90% | −2.83% | +50.29% | +40.64% |
| Today | +5.02% | +2.79% | +2.63% | −1.25% | +2.41% | +2.59% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All MRCK34.SA news ›Merck to divest CDMO business across five US sites to Lonza
Merck has signed a definitive agreement to sell its CDMO business to Lonza for a mid-triple-digit million-euro sum, with the transaction expected to complete in mid-2027. Merck has agreed to divest its contract development and…
More from 1 other outlet
Lonza buys Merck CDMO in Germany to double U.S. footprint as Korea rivals race
Deal adds five U.S. sites as Samsung Biologics and Celltrion accelerate global capacity grabs Lonza, the world's No. 1 biopharmaceutical CDMO company, is expanding its U.S. production foothold and bulking up. Korean corporations Samsung…
Merck’s Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.
Merck just posted its sixth straight earnings beat and its CEO is targeting $70 billion in mid-2030s revenue, yet the stock carries a looming patent cliff that could reshape everything. Whether the pipeline saves the story or the bears…
Lonza to Buy Five Merck Drug-Manufacturing Plants, Including Carlsbad Site
One asset is explicitly staying put. BioReliance Contract Testing Services is not included in the transaction and will remain an important part of Merck's Life Science portfolio, the company said in its statement. Until the sale closes,…
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt…
Lonza to buy Merck KGaA’s contract manufacturing business
The Swiss contract development and manufacturing organization (CDMO) Lonza has agreed to buy the drug services business of Germany’s Merck KGaA. The purchase will give Lonza five new manufacturing sites in the US, doubling the company’s US…
More from 1 other outlet
Merck and Company Rises on NYSE: MRK as CCI Extends Beyond Band and EPS Base Resets
Merck & Company Inc (NYSE: MRK) Gains 2.18% With CCI Extended and P/E Reflecting Low EPS Base Merck & Company, Inc. (NYSE: MRK) rose 2.18% in the latest session. An in-depth look at the transitional EPS base, extended CCI, and broader…
Portfolio reshuffle: Lonza buys Merck KGaA's CDMO arm
The sale gives Lonza added US manufacturing capacity and extends its run of portfolio reshaping, while Merck KGaA sharpens its life science focus. Germany’s Merck has signed an agreement to sell its contract development and manufacturing…
Lonza to Acquire Merck KGaA’s CDMO Business
The acquisition expands Lonza’s U.S. CDMO manufacturing footprint and adds end-to-end development and manufacturing capabilities in the U.S. Editor’s Take: Lonza is buying both specialized manufacturing expertise and a stronger position in…
Merck charts course out of CDMO business with Lonza sale
Merck KGaA has moved to streamline its focus with the sale of its contract development and manufacturing organisation (CDMO) business to Lonza, a top-three player in the category, for "a mid-triple-digit million-euro amount." The deal…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com48
- marketbeat.com32
- seekingalpha.com14
- theglobeandmail.com14
- themarketsdaily.com12
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.